Commit Sales Contribute To 25% Gain In GSK Smoking Cessation Sales In Q4
This article was originally published in The Tan Sheet
Executive Summary
Sales of GlaxoSmithKline's Commit nicotine polacrilex lozenge helped drive the company's fourth quarter smoking cessation sales to $198 mil., up 25% at constant exchange rates compared with the year-ago period
You may also be interested in...
GSK Respiratory OTC Sales Up 13% In Q1
Sales for GlaxoSmithKline's OTC respiratory tract products, which include the Contac cold and flu remedy, rose 13% to $57.7 mil. (£1=$1.60) during the first quarter, the firm announced April 30. Contac primarily is marketed in the U.S., UK, Mexico, China and Japan
GSK Respiratory OTC Sales Up 13% In Q1
Sales for GlaxoSmithKline's OTC respiratory tract products, which include the Contac cold and flu remedy, rose 13% to $57.7 mil. (£1=$1.60) during the first quarter, the firm announced April 30. Contac primarily is marketed in the U.S., UK, Mexico, China and Japan
GSK Respiratory OTC Sales Up 13% In Q1
Sales for GlaxoSmithKline's OTC respiratory tract products, which include the Contac cold and flu remedy, rose 13% to $57.7 mil. (£1=$1.60) during the first quarter, the firm announced April 30. Contac primarily is marketed in the U.S., UK, Mexico, China and Japan